

Notification of Medical Policy Revisions: February 2016

Medical Policy	Revision
Oral Antiemetic Medications	<p>Staff clarification and consistency with CMS guidance. Title changed to Oral Antiemetic Medications to reflect LCD L33827. Policy Statement – added statement referencing the Oral Anticancer Medications medical policy for coverage information of antiemetic medications used in conjunction with oral anticancer medications per the LCD. Indications For Coverage – updated and reformatted language to align more closely with LCD and removed criteria referencing antiemetic medications used in conjunction with oral anticancer medications – moving this language into the Oral Anticancer Medications medical policy for consistency with CMS guidance. Reformatted item C and removed the name Akynzeo as it was removed from the LCD, added clarifying language to the 5th bullet and removed language “intravenous highly emetogenic or moderately emetogenic” as this is not indicated in the LCD. When Coverage Will Not Be Approved – added item #2 for consistency with the LCD. Removed duplicate code.</p>
Skilled Care Services	<p>Update to CMS guidance via MLN MM1436 Certifying Patients for the Medicare Home Health Benefit, effective 1/1/2016. Indications For Coverage – added item #5 face-to-face encounter with a physician or non-physician provider as a requirement for coverage. Re-formatted policy for better policy continuity.</p>
Oral Anticancer Medications	<p>Staff clarification regarding confirmation that the oral anticancer medications listed are equivalent to the IV/injectable form of the same medications. Descriptions of Procedure/Service – added language indicating the IV equivalent or prodrug indications for each drug listed as indicated in LCD L33826 with information provided on FDA.gov website. Indications For Coverage – moved item #2 from the Oral Antiemetic Medications to this medical policy for continuity with CMS guidance. When Coverage Will Not Be Approved – added item #2 from the Oral Antiemetic Medications medical policy per the LCD. Special Notes – added language to 1st bullet for staff clarification per LCA A52479.</p>